nkg2dl-targetting chimeric antigen receptor-grafted gamma delta t cell
Cell therapyexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Dec 1, 2019 (NCT04107142)
Timeline
2010s
- Jan 1, 2019
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- NKG2-D type II integral membrane proteinImmunity, passive
immunity, passive - KLRK1
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05302037 | Phase 1 | Apr 30, 2022 | CytoMed Therapeutics Pte Ltd, National University of Singapore |
| NCT04107142 | Phase 1 | Dec 1, 2019 | CytoMed Therapeutics Pte Ltd |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| CytoMed Therapeutics Pte Ltd | For profit | 2 | 2 | 1 | 2019 |
| National University of Singapore | Academic/Hospital | 1 | 0 | 1 | 2022 |
2 organizations
Page 1 / 1